IL17A and irritable bowel syndrome: Treatment of ALW-II-41-27 (12.5, 25, and 50 μg/kg) significantly reduced TNF-α,IL-6, IL-17, and ICAM-1, and significantly increased the level of IL-10, compared with PI-IBS model group (P < 0.01).